Back to Newsroom

Curis and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration

LEXINGTON, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today announced that it has exercised its option to extend the exclusivity period with Aurigene under the collaboration, license and option agreement established in January, 2015.  As previously reported, the extension of exclusivity is associated with a payment of $7.5 million to Aurigene, payable in two equal installments in the first and third quarters of 2017.

Click here to read the full release